Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 May;176(5):eL230049.
doi: 10.7326/L23-0049. Epub 2023 Mar 21.

Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Katherine Mackey, Devan Kansagara, Kathryn Vela  1
Affiliations
Comment

Update Alert 10: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Katherine Mackey et al. Ann Intern Med. 2023 May.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Authors have reported no disclosures of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L23-0049.

Comment on

References

    1. Mackey K, King VJ, Gurley S, et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. A living systematic review. Ann Intern Med. 2020;173:195-203. [PMID: ] doi:10.7326/M20-1515 - DOI - PMC - PubMed
    1. Jardine MJ, Kotwal SS, Bassi A, et al; CLARITY trial investigators. Angiotensin receptor blockers for the treatment of Covid-19: pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ. 2022;379:e072175. [PMID: ] doi:10.1136/bmj-2022-072175 - DOI - PMC - PubMed
    1. Puskarich MA, Ingraham NE, Merck LH, et al; Angiotensin Receptor Blocker Based Lung Protective Strategies for Inpatients With COVID-19 (ALPS-IP) Investigators. Efficacy of losartan in hospitalized patients with COVID-19-induced lung injury: a randomized clinical trial. JAMA Netw Open. 2022;5:e222735. [PMID: ] doi:10.1001/jamanetworkopen.2022.2735 - DOI - PMC - PubMed
    1. Freilich D, Victory J, Jenkins P, et al. COVIDMED - an early pandemic randomized clinical trial of losartan treatment for hospitalized COVID-19 patients. Contemp Clin Trials Commun. 2022;29:100968. [PMID: ] doi:10.1016/j.conctc.2022.100968 - DOI - PMC - PubMed
    1. Duarte M, Pelorosso F, Nicolosi LN, et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962. [PMID: ] doi:10.1016/j.eclinm.2021.100962 - DOI - PMC - PubMed

Substances